Join an adrenal cancer registry for adrenocortical carcinoma
Part of Cancer, Hormones & metabolism clinical trials.
This trial is a registry that collects information from people diagnosed with adrenocortical carcinoma (a rare cancer of the adrenal gland). It can help doctors understand the disease and improve future care by tracking outcomes and treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of adrenocortical carcinoma based on a tissue biopsy (histology).
- Your diagnosis must be documented in medical records or pathology reports.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at adrenal tumors found on imaging (scans) to better understand what causes them and how they might be treated. If you have an adrenal tumor on a scan, this trial may be looking to enroll you for that purpose.
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
This study follows adults with a new adrenal diagnosis to learn how adrenal diseases behave over time. It may help doctors better understand these conditions and improve future care.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Hear when a new Adrenocortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.